You are here

  • Home
  • Archive
  • Volume 2, Issue 1
  • Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Article metrics

Article menu

Download PDFPDF

Research Article
Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2025

AbstractFullPdf
Dec 2019440
Jan 2020881
Feb 202013134
Mar 202010102
Apr 2020994
May 202011112
Jun 202011111
Jul 202012120
Aug 202013131
Sep 202022223
Oct 202035350
Nov 202022223
Dec 202015153
Jan 202118184
Feb 202118186
Mar 202115151
Apr 202126268
May 20212882894
Jun 202115152
Jul 202118186
Aug 2021252511
Sep 2021292916
Oct 2021454512
Nov 2021393910
Dec 202122229
Jan 202221236
Feb 2022253010
Mar 202226278
Apr 202217181
May 202235355
Jun 202237388
Jul 2022363912
Aug 202234343
Sep 202231312
Oct 2022364310
Nov 20227912512
Dec 202283837
Jan 202338383
Feb 202389891
Mar 2023464713
Apr 20239913
May 20231681699
Jun 20231311316
Jul 202312127
Aug 2023994
Sep 20231281287
Oct 202366666
Nov 202317176
Dec 202335354
Jan 2024626313
Feb 202459607
Mar 202424242
Apr 202417215
May 202421216
Jun 202429303
Jul 202425269
Aug 202436415
Sep 202416164
Oct 2024151513
Nov 202435369
Dec 2024575813
Jan 2025282812
Feb 2025434325
Mar 202528287
Apr 2025444410
May 202521226
Jun 202519196
Jul 2025110
Aug 2025110
Total25322617431